THE Therapeutic Goods Administration (TGA) has approved Janssen Australia's first-in-class multiple myeloma therapy that activates the immune system of multiple myeloma patients to attack and kill cancer cells.
Approved for both monotherapy and combination therapy, Darzalex (daratumumab), is the first CD38-directed monoclonal antibody approved for use in Australia, Janssen said in a release.
Darzalex is not funded on the PBS but there are around 1,600 new diagnoses and 900 deaths annually in Australia from the blood cancer disease.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Jul 17